StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$3.61−0.19 (-5.00%)

Close on Nov 20, 2026Market cap $87.45MP/E –Yield –

Exagen gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Exagen's gross profit for the twelve months ending Jun 30, 2026 was $41.70M, up 19.2% year over year. For fiscal 2025 it was $38.80M, up 17.2% from the year before. The highest annual figure on record is $38.80M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$38.80M+17.2%
FY2024Dec 31, 2024$33.11M+12.4%
FY2023Dec 31, 2023$29.46M+38.0%
FY2022Dec 31, 2022$21.35M-23.0%
FY2021Dec 31, 2021$27.71M+9.0%
FY2020Dec 31, 2020$25.42M+17.8%
FY2019Dec 31, 2019$21.58M+26.5%
FY2018Dec 31, 2018$17.06M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.22M+17.5%
Q1 FY2026Mar 31, 2026$10.21M+11.9%
Q4 FY2025Dec 31, 2025$9.21M+8.6%
Q3 FY2025Sep 30, 2025$10.08M+44.3%
Q2 FY2025Jun 30, 2025$10.40M+14.8%
Q1 FY2025Mar 31, 2025$9.12M+6.1%
Q4 FY2024Dec 31, 2024$8.48M+4.1%
Q3 FY2024Sep 30, 2024$6.98M-9.4%
Q2 FY2024Jun 30, 2024$9.06M+9.1%
Q1 FY2024Mar 31, 2024$8.60M+62.1%
Q4 FY2023Dec 31, 2023$8.15M+24.8%
Q3 FY2023Sep 30, 2023$7.71M-11.6%
Q2 FY2023Jun 30, 2023$8.30M+443.3%
Q1 FY2023Mar 31, 2023$5.30M+15.9%
Q4 FY2022Dec 31, 2022$6.53M-15.8%
Q3 FY2022Sep 30, 2022$8.72M+28.9%
Q2 FY2022Jun 30, 2022$1.53M-79.1%
Q1 FY2022Mar 31, 2022$4.58M-22.1%
Q4 FY2021Dec 31, 2021$7.75M-7.0%
Q3 FY2021Sep 30, 2021$6.76M+5.1%
Q2 FY2021Jun 30, 2021$7.32M+30.5%
Q1 FY2021Mar 31, 2021$5.88M+16.6%
Q4 FY2020Dec 31, 2020$8.33M–
Q3 FY2020Sep 30, 2020$6.43M-35.9%
Q2 FY2020Jun 30, 2020$5.61M+2.3%
Q1 FY2020Mar 31, 2020$5.04M+4.6%
Q4 FY2019Dec 31, 2019-$7.49M-232.9%
Q3 FY2019Sep 30, 2019$10.04M+129.7%
Q2 FY2019Jun 30, 2019$5.48M–
Q1 FY2019Mar 31, 2019$4.82M–
Q4 FY2018Dec 31, 2018$5.64M–
Q3 FY2018Sep 30, 2018$4.37M–

More Exagen figures

See a number that looks wrong?